List view / Grid view

Issue #1 2019

 

article

AI-driven automated chemistry as a tool to accelerate drug discovery

15 May 2019 | By

Typically, early drug discovery campaigns start with the screening of chemical libraries to identify candidate chemotypes modulating a particular target and/or phenotype. Success of the primary screening depends on multiple factors related to both biology and chemistry. These include the target’s druggability, sensitivity and specificity of assay system, composition and…

article

Squaring the circle – cancer vaccines

8 May 2019 | By

By the 1890s William B. Coley had injected streptococcal organisms in patients with solid tumours (“Coley’s Toxins”) to activate the immune system. Coley (1862-1936) was an American bone surgeon and pioneer of cancer immunotherapy. He was convinced that post-surgical infections had helped patients to recover better from their cancer by…

article

Transforming drug discovery, development and delivery with flow chemistry

11 April 2019 | By ,

Flow chemistry is on the rise thanks to the commercial availability of benchtop continuous flow systems that has driven widespread adoption of the technique across a broad range of applications in both academia and industry. In particular, flow chemistry is delivering significant benefits in the area of drug discovery and…

article

The importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays

21 March 2019 | By ,

Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.

article

Cell line development – global market drivers, trends and its impact on improving biologics development from early phase to IND during the drug discovery process

19 March 2019 | By

Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies,…

article

Lab Automation In-Depth Focus 2019

18 March 2019 | By

In this In-Depth Focus: realising the promise of laboratory automation in biomedical research, drug discovery from the age of information to the age of intelligence, and transforming drug discovery, development and delivery with flow chemistry.

article

Assays In-Depth Focus 2019

14 March 2019 | By

In this In-Depth Focus: the importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays, and why do we have no effective treatments for osteoarthritis?